Cairo

Running trials

• Recruiting

  Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo

  NCT07069829· Source

• Recruiting

  Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

  NCT07221331· Source

• Recruiting

  A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region

  NCT07065344· Source

• Recruiting

  INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

  NCT06314282· Source

• Active, not recruiting

  Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.

  NCT05817110· Source

• Active, not recruiting

  Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

  NCT05301842· Phase 3· Source

• Recruiting

  iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases

  NCT03549754· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lupus (SLE)1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Completed

  UNFOLD Study Egypt

  NCT06188494· Source

• Completed

  PROPE Severe Asthma Study in Egypt

  NCT06283290· Source

• Completed

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· Phase 3· Source